XML 14 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]        
Molecular diagnostic testing $ 179.7 $ 185.2 $ 537.6 $ 534.2
Pharmaceutical and clinical services 13.8 11.7 40.1 36.7
Total revenue 193.5 196.9 577.7 570.9
Costs and expenses:        
Cost of molecular diagnostic testing 36.8 37.9 110.7 109.5
Cost of pharmaceutical and clinical services 7.3 6.4 20.7 19.1
Research and development expense 18.5 17.6 53.1 55.6
Change in the fair value of contingent consideration (1.2) 5.2 (61.3) 2.0
Selling, general, and administrative expense 115.1 122.1 345.5 354.3
Total costs and expenses 176.5 189.2 468.7 540.5
Operating income 17.0 7.7 109.0 30.4
Other income (expense):        
Interest income 0.5 0.3 1.2 0.9
Interest expense (0.5) (1.5) (2.2) (4.8)
Other (0.5) 1.5 (1.3) (2.4)
Total other income (expense): (0.5) 0.3 (2.3) (6.3)
Income before income tax 16.5 8.0 106.7 24.1
Income tax provision 5.2 3.8 (17.7) 15.2
Net income 11.3 4.2 124.4 8.9
Net loss attributable to non-controlling interest (0.1)   (0.2) (0.1)
Net income attributable to Myriad Genetics, Inc. stockholders $ 11.4 $ 4.2 $ 124.6 $ 9.0
Earnings per share:        
Basic $ 0.16 $ 0.06 $ 1.80 $ 0.13
Diluted $ 0.16 $ 0.06 $ 1.74 $ 0.13
Weighted average shares outstanding:        
Basic 69.8 68.1 69.2 68.1
Diluted 72.4 68.3 71.7 68.5